Beam Therapeutics Inc (BEAM) Price

Mr. John Evans is the Chief Executive Officer of Beam Therapeutics Inc, joining the firm since 2017.

The current price of BEAM is $24.75, it has decreased 1.43% in the last trading day.

Beam Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care

Beam Therapeutics Inc's current market cap is $2.5B

According to wall street analysts, 16 analysts have made analyst ratings for Beam Therapeutics Inc, including 9 strong buy, 10 buy, 3 hold, 0 sell, and 9 strong sell

Looks like BEAM is getting a shot of hopium, anon. The stock is rallying on renewed analyst optimism, specifically around its BEAM-302 gene-editing program, even though the company pushed back some data readouts. The technicals show strong buying pressure, but it's approaching a key resistance level.

The move in Beam Therapeutics today is a classic case of fundamentals and technicals aligning. Here’s the breakdown:

• Fundamental Catalyst: Analyst Hype The main driver is a recent wave of positive sentiment from analysts, particularly BMO Capital, regarding Beam's BEAM-302 DNA editing program. Management has been signaling high confidence in their tech, and the company has been actively presenting at healthcare conferences over the past week, increasing its visibility. However, they also made a strategic call to delay key data readouts until early 2026 to ensure a more robust regulatory update, which is a long-term positive but removes a short-term catalyst.

• Technical Momentum: Bullish but Toasty The chart is confirming the bullish narrative, but you need to watch your entry.

  • Daily Chart: The price is trading above its 50-day moving average ($19.10), a bullish sign. The daily RSI is at 62.68, showing strong momentum but not yet in the "overbought" zone (above 70). The MACD also shows a clear bullish trend since early September. The main hurdle is the 200-day moving average, currently sitting around $21.74, which will act as significant resistance.
  • Hourly Chart: On the shorter timeframe, the momentum is still there, but the hourly MACD is showing signs of potential consolidation or a slight pullback, suggesting the initial burst might be cooling off intraday.

• Wall Street Sentiment: Strong Buy Analysts are overwhelmingly bullish on BEAM. The consensus rating is a "STRONG_BUY," with an average price target of $45.74—more than double its current price. With 19 out of 22 analysts rating it a Buy or Strong Buy, it's clear the institutional crowd sees long-term value here. There have been no insider sales in the last month, which is a neutral to positive sign.

The play here is a momentum trade backed by strong fundamental sentiment. Just be careful not to ape in at resistance. Maybe watch the 200-day MA before you become exit liquidity for the suits, bro.